Advertisement
We are delighted to announce that Cancer & Metabolism has been accepted for inclusion in Science Citation Index Expanded (SCIE), a key database of Web of Science, published by Clarivate Analytics. Starting 2020, Cancer & Metabolism will be published in the annual Journal Citation Reports, at which point it will receive the associated journal metrics, such as Immediacy Index, Eigenfactor Score, and Journal Impact Factor.
We would like to thank everyone for supporting Cancer & Metabolism and contributing to this success.
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our usual peer review process. We thank referees for their continued support in these challenging times and ask authors for their patience and understanding.
Thumbnail image by Felipe Esquivel Reed, used under Creative Commons Attribution-Share Alike 4.0 license.
Cancer & Metabolism invites you to join our team of reviewers. For consideration, please send your CV with keywords and expertise to rosie.daniel@springer.com.
The biology of tumor cells in breast cancer is complex and relatively unexplored. Cancer & Metabolism is excited to present the following article highlights that identify novel biomarkers and metabolic profiles of different breast cancer subtypes.
- Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities
- Metabolomics of oncogene-specific metabolic reprogramming during breast cancer
Tronstad et al. investigated the role the role of succinate dehydrogenase in relation to Epithelial to mesenchymal transition (EMT) in breast cancer progression and therapy.
Dr. Michael Pollak, co-Editor-in-Chief
Dr. Pollak is an internationally recognized expert in cancer endocrinology at the Lady Davis Institute for Medical Research of McGill University and a clinical oncologist at the Jewish General Hospital, Quebec, Canada.
"Cancer & Metabolism will provide a forum for rapid dissemination of research findings concerning metabolic factors that influence cancer risk and cancer pathophysiology, and cancer treatment. The scope of the Journal will allow for an interdisciplinary readership including cancer biologists, endocrinologists, oncologists, clinical trialists and population scientists."
Dr. Matthew G. Vander Heiden, co-Editor-in-Chief
Dr. Vander Heiden is Associate Director at the Koch Institute for Integrative Cancer Research at MIT. Extensively published in over 140 peer reviewed articles and book chapters, his research interests focus on the metabolic processes of cancer cells, including how glucose metabolism affects tumor growth and how these studies may lead to new developments in targeted cancer therapy. A renowned innovative researcher in his field, Dr. Vander Heiden received the 2017 Philip A. Sharp Innovation in Collaboration Award from Stand Up to Cancer (SU2C).
Abass Alavi, University of Pennsylvania School of Medicine, USA
Lewis Cantley, Weill Cornell Medical College, USA
Peter Carmeliet, Vesalius Research Center, Belgium
Ralph DeBerardinis, University of Texas Southwestern Medical Center, USA
Teresa Fan, Markey Cancer Center, USA
Robert Gatenby, H. Lee Moffitt Cancer Center and Research Institute, USA
Kun-Liang Guan, University of California, San Diego,
Rudolf Kaaks, German Cancer Research Center, Germany
Andrew Lane, Markey Cancer Center, USA
Gordon Mills, University of Texas M. D. Anderson Cancer Center, USA
Lorenz Poellinger, Karolinska Institute, Sweden
Jacques Pouyssegur, Institute of Research on Cancer and Aging, France
Joshua Rabinowitz, Princeton University, USA
Peter Ratcliffe, Nuffield Department of Clinical Medicine, UK
Jeffrey Rathmell, Duke University, USA
Jared Rutter, University of Utah School of Medicine, USA
David Sabatini, Whitehead Institute for Biomedical Research, USA
Paolo Sassone-Corsi, University of California, Irvine, USA
Gregg Semenza, Johns Hopkins University School of Medicine, USA
Celeste Simon, University of Pennsylvania School of Medicine, USA
Alexei Vazquez, The Cancer Institute of New Jersey, USA
Bert Vogelstein, Johns Hopkins University School of Medicine, USA
Karen Vousden, Beatson Institute for Cancer Research, UK
Kathryn Wellen, University of Pennsylvania, USA
Eileen White, The Cancer Institute of New Jersey, USA
Yue Xiong, University of North Carolina, Chapel Hill, USA
Chi Van Dang, Editor Emeritus
Chi Dang is a professor, physician-researcher, renowned cancer biologist and hematologist-oncologist, who serves as director of the Abramson Cancer Center at the University of Pennsylvania.
"After several decades of profound advances in our understanding of the genetics and molecular biology of cancer, it has become self-evident that metabolism and bioenergetics are regulated by cancer genes and are intimately linked to the growth and survival of cancer cells. The obesity pandemic connected to increased cancer risk further underscore the importance of a richer understanding of cancer and organismal metabolism. In this regard, Cancer & Metabolism is launched uniquely to fulfill the needs of a burgeoning field which is at the crossroads of many scientific disciplines."
We recognize that scientifically sound, high-quality manuscripts often receive negative decisions from high-impact journals on the basis of perceived general interest levels or the absence of extensive mechanisms supporting research hypotheses. As a niche journal, Cancer & Metabolism will consider rapid publication of such manuscripts if they are submitted together with the original peer reviewer reports, letter of rejection, and a brief rebuttal.
Advertisement
Speed
65 days to first decision for reviewed manuscripts only
59 days to first decision for all manuscripts
135 days from submission to acceptance
35 days from acceptance to publication
Citation Impact
1.886 - Source Normalized Impact per Paper (SNIP)
3.928 - SCImago Journal Rank (SJR)
Usage
140,853 Downloads
210 Altmetric Mentions
Advertisement
Cancer & Metabolism
